Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Is the BCG vaccine a useful tool against COVID-19?

Galina Zhelezova, MD, PhD\textsuperscript{a}, Valeria Mateeva, MD, PhD\textsuperscript{b}, Grisha Mateev, MD, PhD\textsuperscript{b,*}

\textsuperscript{a} Department of Biology, Medical Genetic, and Microbiology, Medical Faculty, Medical University, Sofia, Bulgaria
\textsuperscript{b} Department of Dermatology and Venereology, Medical Faculty, Medical University, Sofia, Bulgaria

Abstract The Bacillus Calmette–Guérin (BCG) vaccine has been used since 1921 initially for protection against tuberculosis. BCG acts through stimulation of cell-mediated adaptive immunity with activation of the Th1 cells and production of interferon gamma. Additionally, it is able to stimulate the immune system in a nonspecific manner, which results in effectiveness of the BCG against non-mycobacterial infections and in some malignant, autoimmune, and inflammatory diseases. Recently, its potential use in the fight against the coronavirus disease 2019 (COVID-19) pandemic has been suggested. This is based upon the concept of BCG-induced trained innate immunity—a memory-like response of the innate immune system that can realize greater protection in case of re-infection. This hypothesis represents a milestone in the potential use of the BCG vaccine in the fight with the novel coronavirus.

The Bacillus Calmette–Guérin (BCG) vaccine: history and present

Bacillus Calmette–Guérin (BCG) vaccine was launched in 1921 and is the only vaccine currently in use for protection against tuberculosis (TBC)—the disease that is one of the top 10 causes of death and the leading cause of death from a single infectious agent in the world.\textsuperscript{1,2}

The BCG vaccine was created by two French scientists: Albert Calmette (1863-1933) and Camille Guérin (1872-1961) from the Pasteur Institute, Lille, France. After 13 years of trying to subculture the \textit{Mycobacterium bovis} strain on bile-potato medium, they finally succeeded in obtaining a newly less virulent strain, possibly as a result of genetic changes. The strain was first used for immunization of humans in 1921. The \textit{M bovis} BCG (live attenuated strain of \textit{M bovis} by Calmette and Guren) was initially used in its oral form. Subsequently, it became generally accepted that the most accurate method of BCG vaccination is intradermal ap-

\textsuperscript{*} Corresponding author.

E-mail address: grisha_mateev@yahoo.com (G. Mateev).

https://doi.org/10.1016/j.clindermatol.2020.12.018
0738-081X/© 2020 Elsevier Inc. All rights reserved.
The names of the strains reflect the country or the laboratory in which they are produced.\textsuperscript{7} The schedule for BCG vaccination for TBC prevention is not the same in different geographic areas and varies according to the local epidemiology of the disease.\textsuperscript{8} Generally, the first dose of the BCG vaccine is given in infancy, which is often followed by additional vaccinations throughout childhood. In some countries, the schedule for revaccination is universal, whereas in others the revaccination is performed based on the lack of tuberculin sensitivity or the absence of a typical scar.\textsuperscript{8} The official recommendation of the World Health Organization (WHO) is a single dose of BCG in infancy. It includes vaccination of all newborns in countries with a high incidence of TBC and a high risk for potential complications such as meningitis and sepsis.\textsuperscript{9}

The use of BCG vaccine for routine immunization has decreased or has been discontinued due to the low rate of TB in many industrialized countries, although selective vaccination of high-risk groups may still be performed. In some countries, such as the Netherlands and the United States, BCG vaccination was never included in their national immunization programs.

Effectiveness of BCG vaccine and mechanism for induction of specific immunity in TB

The BCG vaccine acts through stimulation of the cell-mediated adaptive immune response and activation of Th1 immunity.\textsuperscript{10} Such immunization with BCG leads to activation of CD4+ and CD8+ T-cells and increased production of interferon (IFN)-gamma. This cytokine, INF-gamma, plays a key role in the anti-mycobacterial activity of the macrophages and stimulates B-cells to produce antigen-specific antibodies.

Two important aspects of the immunity induced by BCG vaccination in the host are not understood:

1. The duration of the BCG-induced immune response
2. The mechanism for vaccine-induced cell-mediated immunity\textsuperscript{11,12}

Similarly, the clinical effectiveness of the BCG vaccine continues to be controversial.\textsuperscript{13} Observations on its safety and effectiveness made in the 1940s and 1950s were reviewed in the early 1990s with the conclusion that the BCG vaccine has a good safety profile; however, efficacy against pulmonary tuberculosis could not be shown.\textsuperscript{14}

Today, on the basis of large-scale randomized, controlled clinical trials, and case-control studies, it is broadly accepted that the BCG vaccine induces significant specific protection in patients with tubercular neonatal meningitis and in children with disseminated tuberculosis. There is almost no effect in adults and the elderly or in those with latent TB infection.\textsuperscript{15} Based on these studies, the effectiveness of BCG is considered to be only partially effective against TB and should be limited for use in children.\textsuperscript{16,17} Studies on the effectiveness of the BCG vaccination against meningitis and miliary tuberculosis in neonates are inconsistent.\textsuperscript{18}

Hypothetically, these differences in the effectiveness of the BCG vaccine could be due to genetic variations in the vaccine strains, variations in the immunization schedules, genetic variations of the host, or interference of the human immunity with certain parasites.\textsuperscript{19-21} The last is explained by the interplay between Th2-immune response against parasites and Th1-response that predominates in TB infection.

Despite the unsolved questions about the effectiveness of the BCG vaccine, this century-old vaccine remains the only registered vaccine against TB and continues to be used worldwide.\textsuperscript{22} BCG also has consistent benefits in protection against leprosy.\textsuperscript{23-25} Mycobacterium leprae is a member of the same genus Mycobacteria as M bovis and has common antigenic determinants with the BCG vaccine strain.

Nonspecific immune stimulation and effectiveness of BCG against infections, other than TBC, and in malignant, autoimmune, and inflammatory diseases

A well-established hypothesis is that BCG stimulates the immune system in a nonspecific manner; for example, BCG is currently used for the treatment of some types of malignancies, including bladder cancer and multiple myeloma. The induction of the immune response is attributed to nonspecific mechanisms.\textsuperscript{26,27} The action of BCG vaccine in some inflammatory and autoimmune diseases\textsuperscript{28} may be mediated by the impact of the vaccine on the cytokine production of T-regulatory cells (T-regs) and Th17 lymphocytes.

BCG may have nonspecific beneficial effects in children from both developing and developed countries by reducing morbidity and mortality unrelated to M tuberculosis. Several clinical studies from different geographic areas, mostly involving children, suggest a nonspecific protective effect of the BCG vaccine against bacterial and viral infections; for example, BCG vaccination in neonates influences the immune response to standard vaccines given in early life.\textsuperscript{29} These results are attributed to the adjuvant effect of BCG vaccine through stimulating the maturation of the dendritic cells.

A case-control study\textsuperscript{30} in Guinea-Bissau showed a beneficial effect of BCG vaccination against acute lower respiratory tract infections and respiratory syncytial virus in infants. A randomized clinical trial\textsuperscript{31} showed a 17% decline in the mortality of low-birth-weight children from West Africa who were BCG-immunized in the previous year. This report favored the beneficial effect of the BCG vaccine against other infections. Similar results have been reported in a small randomized controlled study in neonates,\textsuperscript{32} where there was a lower mortality from infections in the BCG-vaccinated cohort.
The beneficial effect of the BCG immunization on the resistance to non-TBC infections has been confirmed by two randomized clinical trials in Guinea-Bissau, where a 45% reduction of overall mortality has been reported in vaccinated neonates. Similar results are found in Spain with BCG-vaccinated and nonvaccinated children. There was an average of 40% decrease in hospitalization due to respiratory infections, and sepsis not related to tuberculosis was observed in immunized children. Two additional case-control studies found the protective effect of BCG vaccination in children against lower respiratory tract infections and bacteremia-related mortality.

A global prospective study across 19 countries conducted over a period of 25 years again showed that the BCG immunization is associated with 17% to 37% of reduction of suspected acute lower respiratory infections in children <5 years of age. Several clinical studies have focused on the nonspecific protective effect of the BCG vaccination in adults and the elderly. BCG immunization in patients over 65 years old with comorbidities may decrease the risk of developing pneumonia. A single dose of BCG vaccine monthly for three consecutive months may significantly reduce the risk of acute upper respiratory tract infections in this age group through increasing Th1 and T-reg immune responses.

A randomized, placebo-controlled pilot study on healthy adults has shown that BCG vaccination before an influenza vaccination against the 2009 influenza A pandemic resulted in a more pronounced and accelerated induction of functional antibody responses.

**BCG-induced trained innate immunity: a memory-like immune response**

In the last decade, the cellular and molecular mechanisms of nonspecific immunity induced from BCG vaccine have been studied in detail. New facts were obtained and were interpreted in the aspect of nonspecific protection against the COVID-19. The innate immunity represents the first line of defense against infections and realizes nonspecific protection without memory immune responses as it is in the case of adaptive immunity. There are increasing scientific data that innate immune mechanisms can realize greater protection in case of re-infection. This can be interpreted as a memory-like response. Some infections and vaccinations can induce broad protection against other pathogens exactly through innate immune mechanisms. Such innate immune responses with a new type of immunologic memory are known as trained innate immunity.

In the case of the BCG vaccine, the induced trained innate immunity may result from an interaction between toll-like receptors and conservative structures from BCG bacteria cell walls. This leads to epigenetic and metabolic reprogramming of the innate immune cells and development of trained innate immunity. Subsequently, the activated macrophages and NK cells stimulate the production of a number of cytokines, which are characteristic for such acute inflammation, due to tumor necrosis factor (TNF) α and interleukin (IL)-6.

Several scientific groups have investigated whether BCG can stimulate trained innate immunity in infants. There were enhanced innate responses to nonspecific stimuli following infant BCG vaccination in a cohort both in West Africa and in the United Kingdom. Similar results have been reported following neonatal BCG vaccination.

The induction of trained immunity is at least partially responsible for nonspecific cross-protection. This hypothesis, pending rigorous clinical trials, is the milestone for the potential use of the BCG vaccine in the fight with the novel coronavirus.

**BCG vaccine and coronavirus disease (COVID-19)**

Vaccination of adults and the elderly with BCG to prevent infection or reduce the number mortality from COVID-19 is a very attractive idea. There would be no concern about the safety of BCG vaccine. Because COVID-19 is a global health emergency, many clinical trials have been initiated to assess the nonspecific boosting effect on immunity induced by the BCG vaccine. Currently, the data for epidemiology of COVID-19 indicate a lower rate of COVID-19-related mortality in the developing countries with a high level of routine BCG immunization in the general population.

Two large studies on the relation of the previous BCG vaccination and risk of death from COVID-19 are intriguing. In the first multinational study, the authors compare BCG vaccination policy and COVID-19 cases and deaths. The results show a strong correlation between BCG vaccination and incidence of COVID-19 cases. The conclusion is that countries with robust BCG vaccination policies have lower case fatality rates of SARS-CoV-2.

The second recent study also suggests an inverse correlation between BCG vaccination and severe coronavirus disease and mortality rates. The authors consider the influence of a number of factors that can affect the nonspecific effectiveness of BCG vaccine and may explain the broad differences between countries.

A significant inverse correlation between the BCG vaccination index and deaths from COVID-19 has been detected—every 10% increase in the BCG index has been associated with a 10.4% reduction in COVID-19 mortality. The high mortality rates in France and the United Kingdom are possibly a result from the BCG immunization of older children in contrast to Germany and Scandinavian countries, where an early BCG vaccination is routinely performed.
**BCG immunization of adults and elderly: ongoing randomized clinical trials of the BCG vaccine for COVID-19**

A growing number of BCG vaccines presented in a CEBM (Centre for Evidence-Based Medicine) review are currently being investigated in various studies worldwide. The idea in all those trials is to use the BCG vaccine as a potential preventive measure against SARS-CoV-2 for adults and the elderly, who are known to have an increased risk of a severe clinical course of COVID-19 and death. Catch Health Technology Review has reported information about 16 controlled randomized clinical trials (phase II, 1 trial; phase III, 3 trials; phase IV, 12 trials) up to June 23, 2020. All trials have selection criteria and use selected methods of investigation.

Most of the trials have included BCG-immunized subjects who have been at a high risk for infection with the new virus—healthy adult health care workers (HCWs) (medical or nonmedical) from COVID-19 hospitals who are directly being exposed to the virus. There are different BCG strains used:

- Germany and France—a strain recombinant vaccine VPM 1002
- Greece—Moscow strain
- India—Danish strain
- USA—Tice strain
- Netherlands—BCG strain
- Australia and Europe—Danish strain
- South Africa—Danish strain
- Colombia—BCG strain
- Canada—recombinant vaccine VPM 1002

Participants receive a single dose of BCG vaccine intradermally (or placebo) and are followed for 6 to 12 months.

All study participants in the French clinical trial were vaccinated in childhood, because BCG vaccination was mandatory in France for neonates until 2007 and in HCWs until recently. The French study provides a unique situation to evaluate the effect of revaccination with BCG in the context of BCG priming decades before the revaccination.

Interesting results are also expected in the case of trials that use recombinant candidate BCG vaccine VPM 1002. VPM 1002 is based on the traditional BCG vaccine, which was developed at the beginning of the 20th century and is indicated to prevent tuberculosis recurrence. A new study has been recently undertaken in India to investigate the effectiveness of BCG in preventing morbidity and mortality due to COVID-19 in subjects 60 to 95 years of age. The regimen is the same as applied to newborn babies as a part of the national immunization program.

**Discussion**

The hypothesis that BCG vaccination might be a potent preventive measure against SARS-CoV-2 infection and/or may reduce disease severity in high-risk groups is intriguing. It is reasonable to predict a beneficial effect of this vaccine on the basis of the knowledge from epidemiologic studies about the nonspecific cross-protection induced from the BCG vaccine, and from the new information about trained immunity.

There are two important questions arising from current studies:

1. Can the BCG realize basic or at least transient protection against COVID-19 in adults and elderly people? If yes, it will be very useful for high-risk groups—HCWs and patients with comorbidities, such as obesity, diabetes, or cardiovascular diseases. How adults will react to the BCG immunization is not clear. Results from the large number of ongoing prospective randomized clinical trials are awaited.

2. How long does early neonatal BCG immunization provide protective immunity? Many countries in Eastern Europe and some in Asia have active universal BCG immunization programs, and it is possible to compare the protection against COVID-19 in older age with the protection in countries where a routine BCG infant immunization is not applied, such as most of Western Europe and the United States.

Currently, it is well established that BCG vaccine possesses immune-boosting properties, which justify its use in the treatment of several malignancies. A large number of studies confirm its ability to ensure nonspecific protection in children against bacterial and viral respiratory infections. Novel data show that BCG vaccine can stimulate nonspecific immune memory in the context of innate immunity. There is a tendency toward both lower morbidity and mortality from COVID-19 in countries with universal BCG vaccination in childhood.

**Conclusions**

The statement of WHO is that currently there is no sufficient evidence that BCG vaccine can protect people from COVID-19 infection. It is not recommended for prevention of COVID-19 until data from ongoing clinical trials are reported. The Global Alliance for Vaccines and Immunizations has given a similar statement.

Despite the optimism for development of a specific vaccine against SARS-CoV-2, it seems currently unrealistic that it would be globally and rapidly introduced for massive prophylaxis of COVID-19. The only alternative to a specific vaccine is a nonspecific stimulation of immunity that will increase the chances for resistance to the novel coronavirus and
thus decrease related morbidity and mortality. BCG vaccine could provide basic or even partial protection against SARS-CoV-2. Such ongoing clinical trials with the BCG immunization of risk groups could provide the immune-boosting potential of the BCG vaccine and justify its application for COVID-19 protection.

References

1. Dye C. Making wider use of the world’s most widely used vaccine: Bacille Calmette-Guerin revaccination reconsidered. J R Soc Interface. 2013;10.
2. World Health Organization. WHO tuberculosis key facts 2020. Available at: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed on 2 Aug 2020.
3. Romani N, Flacher V, Tripp CH, et al. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol. 2012;351:113–138.
4. Osborn TW. Changes in BCG strains. Tuberulce. 1983;64:1–13.
5. Behr MA. BCG—different strains, different vaccines? Lancet Infect Dis. 2002;2:86–92.
6. Abdallah AM, Behr MA. Evolution and strain variation in BCG. Adv Exp Biol Med. 2017;1019:155–169.
7. Smith KC, Orme IM, Starke JR. Tuberculosis vaccines. Vaccines. 2012;799–811.
8. Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. World Health Organization. Issues relating to the use of BCG in immunization programs: A discussion document. 1999 Available at: https://apps.who.int/iris/handle/10665/66210. Accessed on 2 Aug 2020.
9. World Health Organization. Bacille Calmette-Guérin (BCG) vaccination and COVID-19; 2020 Available at: https://www.who.int/publications/i/item/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19. Accessed on 29 Jul 2020.
10. Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years? Front Immunol. 2017;8:1134.
11. Kagiwa BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med. 2010;182:1073–1079.
12. Mittrucker HW, Steinhoff U, Kohler A, et al. Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A. 2007;104:12434–12439.
13. Orme IM. The Achilles heel of BCG. Tuberculosis. 2010;90:329–332.
14. Gavi.. Can the BCG vaccine protect against COVID-19? 2020 Available at: https://www.gavi.org/vaccineswork/can-bcg-vaccine-protect-against-covid-19. Accessed on 2 Aug 2020.
15. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: A meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–1180.
16. Bonfachich E, Chort M, Astigarraga A, et al. Protective effect of Bacillus Calmette-Guérin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease. A case-control study in Rosario, Argentina. Vaccine. 2006;24:2894–2899.
17. Mangtani P, Abubakar I, Ariri C, et al. Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470–480.
18. Tuberculosis Control Program and Expanded Programme on Immunization: Efficacy of infant BCG immunization. Wkly Epidemiol Rec. 1986;216:218–219.
19. Brosch R, Gordon SV, Garnier T, et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007;104:5596–5601.
20. Fine PE, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med. 1999;341:1226–1227.
21. Labeaud AD, Malhotra I, King MJ, King CL, King CH. Do antenatal parasite infections devalue childhood vaccination? PLoS Negl Trop Dis. 2009;3:e442.
22. Starke JR. Bacille Calmette-Guérin vaccine. Semin Pediatr Infect Dis. 1991;2:153–158.
23. Bertolli J, Pangi C, Frerichs R, Halloran ME. A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar. Int J Epidemiol. 1997;26:888–896.
24. Thuc NV, Abel L, Lap VD, Oberti J, Lagrange PH. Protective effect of BCG against leprosy and its subtypes: A case-control study in southern Vietnam. Int J Lepr Other Mycobact Dis. 1994;62:532–538.
25. Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: Review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines. 2010;9:209–222.
26. Buffen K, Oosting M, Quintin J, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathogens. 2014;10.
27. JH Stewart, Levine EA. Role of bacillus Calmette-Guerin in the treatment of advanced melanoma. Expert Rev Anticancer Ther. 2011;11:1671–1676.
28. Kowalewicz-Kulbat M, Locht C. BCG and protection against inflammatory and auto-immune diseases. Expert Rev Vaccines. 2017;16:1–10.
29. Ota MO, Vekemans J, Schlegel-Hauter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol. 2002;168:919–925.
30. Stensballe LG, Nante E, Jensen IP, et al. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: A beneficial effect of BCG vaccination for girls community based case-control study. Vaccine. 2005;23:1251–1257.
31. Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial nonspecific effects in the neonatal period? J Infect Dis. 2011;204:245–252.
32. Biering-Sorensen S, Aaby P, Napira BM, et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guerin vaccination at first health center contact. Pediatr Infect Dis J. 2012;31:306–308.
33. Biering-Sorensen S, Aaby P, Lund N, et al. Early BCG-Denmark and neonatal mortality among infants weighing <2500 g: A randomized controlled trial. Clin Infect Dis. 2017;65:1183–1190.
34. de Castro MJ, Pardo-Seco J, Martínón-Torres F. Nonspecific (heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis. Clin Infect Dis. 2015;61:1611–1619.
35. Niobey FM, Duchiaide MP, Vasconcelos AG, et al. Risk factors for death caused by pneumonia in children younger than 1 year old in a metropolitan region of southeastern Brazil. A case-control study. Revista Saude Publica. 1992;26:229–238.
36. Chisti MJ, Salam MA, Ahmed T, et al. Lack of BCG vaccination and other risk factors for bacteremia in severely malnourished children with pneumonia. Epidemiol Infect. 2015;143:799–803.
37. Holm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children. Pediatr. 2014;133:e73–e81.
38. Ohru T, Nakayama K, Fukushima T, Chiba H, Sasaki H. Prevention of elderly pneumonia by pneumococcal, influenza and BCG vaccinations. Nihon Ronen Igakkai Zasshi [Jap J Geriatr]. 2005;42:34–36.
39. Wardhana Datau EA, Sultana A, Mandang VV, Jim E. The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly. Acta Med Indonesiana. 2011;43:185–190.
40. Leentjens J, Kox M, Stokman R, et al. BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: A randomized, placebo-controlled pilot study. J Infect Dis. 2015;212:1930–1938.

41. Moorlag S, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019;25:1473–1478.

42. Netea MG, Joosten LA, Latz E, et al. Trained immunity: A program of innate immune memory in health and disease. Science. 2016;352:aaf1098.

43. Arts RJW, Moorlag S, Novakovic B, et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23:89–100 e5.

44. Levy O, Wynn JL. A prime time for trained immunity: Innate immune memory in newborns and infants. Neonatology. 2014;105:136–141.

45. Saeed S, Quintin J, Kerstens HH, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345.

46. Kleinnijenhuis J, Quintin J, Preijers F, et al. BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin Immunol. 2014;155:213–219.

47. Jensen KJ, Larsen N, Biering-Sorensen S, et al. Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: A randomized-controlled trial. J Infect Dis. 2015;211:956–967.

48. Smith SG, Kleinnijenhuis J, Netea MG, Dockrell HM. Whole blood profiling of Bacillus Calmette-Guérin-induced trained innate immunity in infants identifies epidermal growth factor, IL-6, platelet-derived growth factor-AB/BB, and natural killer cell activation. Front Immunol. 2017;8:644.

49. Freyne B, Messina NL, Donath S, et al. Neonatal BCG vaccination reduces interferon-gamma responsiveness to heterologous pathogens in infants from a randomized controlled trial. J Infect Dis. 2020;221:1999–2009.

50. Covian C, Fernandez-Fierro A, Retamal-Diaz A, et al. BCG-induced cross-protection and development of trained immunity: Implication for vaccine design. Front Immunol. 2019;10:2806.

51. Gursel M, Gursel I. Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic? Allergy. 2020;75:1815–1819.

52. Does BCG vaccination protect against acute respiratory infections and COVID-19? 2020. A rapid review of current evidence. Available at: https://www.cceb.net/covid-19/does-bcg-vaccination-protect-against-acute-respiratory-infections-and-covid-19-a-rapid-review-of-current-evidence/. Accessed on 2 Aug 2020.

53. Kothari M, Adeniyi O, Adedoyin A, et al. A multicountry level comparison of BCG vaccination policy and COVID-19 cases and mortality. J Infect Dis Epidemiol. 2020;6:131.

54. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci U S A. 2020;117:17720–17726.

55. ClinicalTrials.gov. Efficacy of BCG vaccination in the prevention of COVID19 via the strengthening of innate immunity in health care workers (COVID-BCG). Available at: https://clinicaltrials.gov/ct2/show/NCT04384549. Accessed on 2 Aug 2020.

56. CADTH. COVID-19, Catch Health Tehtology Review. Ongoing trials for BCG vaccines in prevention of COVID-19, 2020 [updated 26 June 2020]. Available at: https://cadth.ca/sites/default/files/covid-19/hc0007-bcg-vaccines-and-covid-final.pdf. Accessed on 2 Aug 2020.

57. VPM1002 tuberculosis vaccine. VPM1002 tuberculosis vaccine description. 2020. Available at: https://www.precisionvaccinations.com/vacines/vpm1002-tuberculosis-vaccine. Accessed on 26 Jul 2020.

58. Zeenews. ICMR to launch study to evaluate efficacy of BCG vaccine against coronavirus COVID-19 in elderly; Jul 19, 2020 [updated]. Available at: https://zeenews.india.com/india/icmr-to-launch-study-to-evaluate-efficacy-of-bcg-vaccine-against-coronavirus-covid-19-in-elderly-2296746.html. Accessed on 2 Aug 2020.